Novartis Finalizes $23 Billion U.S. Investment Plan with Seventh New Manufacturing Facility
Novartis has reached the final milestone of its $23 billion domestic investment strategy, announcing a seventh new facility in Morrisville, North Carolina. The 56,200-square-foot plant will focus on active pharmaceutical ingredient (API) manufacturing for solid dosage forms and RNA therapeutics. This addition completes a one-year expansion cycle aimed at establishing a fully autonomous, end-to-end supply chain within the United States. By localized production, the Swiss drugmaker seeks to insulate its American patient base from global logistics volatility and potential pharmaceutical import tariffs.
The expansion marks the first time in Novartis’ history that all its advanced technology platforms—including radioligand, cell and gene therapies, and small molecules—will be manufactured domestically. Over the past 12 months, the firm has broken ground on research centers in San Diego and flagship hubs in the Research Triangle, while also building a coast-to-coast radioligand therapy (RLT) network with new sites in Texas, Florida, and California. CEO Vas Narasimhan noted that the connected footprint allows the firm to “locally develop, produce, and deliver medicines at scale.”This surge in infrastructure is designed to provide “timely access to innovation for patients in the U.S.”
Since launching the initiative in April 2025, Novartis has committed to manufacturing all its key medicines for U.S. patients within the country. The Morrisville site specifically complements existing North Carolina facilities focused on biologics and sterile packaging, creating a regional hub for oncology, immunology, and cardiovascular treatments. This infrastructure push coincides with a broader industry shift toward regionalized manufacturing as a hedge against geopolitical uncertainty. As the company nears full operational status for its new sites, it remains on track to integrate discovery and production more tightly than ever before across its 10-site U.S. network.
Sell
Buy
